Use of bisphosphonates and reduced risk of colorectal cancer

Journal of Clinical Oncology

Volumn 29, Issue 9, 2011, Pages 1146-1150

  Rennert, Gad ^a   Pinchev, Mila ^a   Rennert, Hedy S ^a   Gruber, Stephen B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VITAMIN D;

AGED; ARTICLE; BODY MASS; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FOOD INTAKE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK REDUCTION; SPORT;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; ISRAEL; MALE; MENOPAUSE; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79952757671     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.7485     Document Type: Article

References (43)

1. Rosen CJ: Clinical practice: Postmenopausal osteoporosis. N Engl J Med 353:595-603, 2005
2. Aapro M, Abrahamsson PA, Body JJ, et al: Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 19:420-432, 2008
3. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
4. Rennert G, Pinchev M, Rennert HS: Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577-3581, 2010
5. Chlebowski RT, Chen Z, Cauley JA, et al: Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582-3590, 2010
6. Newcomb PA, Trentham-Dietz A, Hampton JM: Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102:799-802, 2010
7. Luckman SP, Hughes DE, Coxon FP, et al: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589, 1998 (Pubitemid 28163009)
8. Russell RG, Watts NB, Ebetino FH, et al: Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733-759, 2008
9. Green JR: Antitumor effects of bisphosphonates. Cancer 97:840-847, 2003 (suppl)
10. Wiemer AJ, Hohl RJ, Wiemer DF: The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anticancer Agents Med Chem 9:526-542, 2009
11. Rachner TD, Singh SK, Schoppet M, et al: Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 287:109-116, 2010
12. Winter MC, Holen I, Coleman RE: Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453-475, 2008
13. Neville-Webbe HL, Holen I, Coleman RE: The anti-tumour activity of bisphosphonates. Cancer Treat Rev 28:305-319, 2002 (Pubitemid 36054539)
14. Wood J, Bonjean K, Ruetz S, et al: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055-1061, 2002 (Pubitemid 34920226)
15. Poynter JN, Gruber SB, Higgins PD, et al: Statins and the risk of colorectal cancer. N Engl J Med 352:2184-2192, 2005 (Pubitemid 40727085)
16. Yizhaki D, Rennert HS, Rosen G, et al: Validity and reproducibility of a semi-quantitative food frequency questionnaire adapted to an Israeli population. Open Nutr J 2:9-14, 2008
17. Center MM, Jemal A, Ward E: International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 18:1688-1694, 2009
18. Ganry O, Lapôtre-Ledoux B, Fardellone P, et al: Bone mass density, subsequent risk of colon cancer and survival in postmenopausal women. Eur J Epidemiol 23:467-473, 2008
19. Zhang Y, Felson DT, Ellison RC, et al: Bone mass and the risk of colon cancer among postmenopausal women: The Framingham study. Am J Epidemiol 153:31-37, 2001 (Pubitemid 32041894)
20. McGlynn KA, Gridley G, Mellemkjaer L, et al: Risks of cancer among a cohort of 23,935 men and women with osteoporosis. Int J Cancer 122:1879-1884, 2008
21. Green J, Czanner G, Reeves G, et al: Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: Case-control analysis within a UK primary care cohort. BMJ 341:c4444, 2010
22. Cardwell CR, Abnet CC, Cantwell MM, et al: Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304:657-663, 2010
23. Powles T, Paterson S, Kanis JA, et al: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219-3224, 2002 (Pubitemid 34831518)
24. Diel IJ, Solomayer EF, Costa SD, et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363, 1998 (Pubitemid 28363797)
25. Clézardin P: The antitumor potential of bisphosphonates. Semin Oncol 29:33-42, 2002 (suppl 21)
26. Stresing V, Daubiné F, Benzaid I, et al: Bisphosphonates in cancer therapy. Cancer Lett 257:16-35, 2007 (Pubitemid 47464698)
27. Green J, Gschaidmeier H, Yoneda T, et al: Zoledronic acid potently inhibits tumour-induced osteolysis in two models of breast cancer metastasis to bone. Ann Oncol 11:14, 2000 (suppl 4)
28. Peyruchaud O, Winding B, Pécheur I, et al: Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: Application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 16:2027-2034, 2001 (Pubitemid 32995393)
29. Nobuyuki H, Hiraga T, Williams PJ, et al: The bisphosphonate zoledronic acid inhibits metastases to bone and liver with suppression of osteopontin production in mouse mammary tumor. J Bone Miner Res 16:S191, 2001 (suppl 1)
30. Sassa S, Okabe H, Nemoto N, et al: Ibandronate may prevent colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Res 29:4615-4619, 2009
31. Tanriverdi HA, Barut A, Sarikaya S: Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. Eur J Obstet Gynecol Reprod Biol 120:63-68, 2005 (Pubitemid 40615074)
32. Staal A, Frith JC, French MH, et al: The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 18:88-96, 2003 (Pubitemid 36008343)
33. Guney E, Kisakol G, Ozgen AG, et al: Effects of bisphosphonates on lipid metabolism. Neuro Endocrinol Lett 29:252-255, 2008 (Pubitemid 351659375)
34. Celiloglu M, Aydin Y, Balci P, et al: The effect of alendronate sodium on carotid artery intimamedia thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 16:689-693, 2009
35. Montagnani A, Gonnelli S, Cepollaro C, et al: Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate. Bone 32:15-19, 2003 (Pubitemid 36175526)
36. Gates MA, Tworoger SS, Eliassen AH, et al: Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 19:1033-1041, 2010
37. Bundred NJ, Campbell ID, Davidson N, et al: Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112:1001-1010, 2008 (Pubitemid 351304583)
38. Loke YK, Jeevanantham V, Singh S: Bisphosphonates and atrial fibrillation: Systematic review and meta-analysis. Drug Saf 32:219-228, 2009
39. Etminan M, Lévesque L, Fitzgerald JM, et al: Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: A case-control study. Aliment Pharmacol Ther 29:1188-1192, 2009
40. Solomon DH, Rekedal L, Cadarette SM: Osteoporosis treatments and adverse events. Curr Opin Rheumatol 21:363-368, 2009
41. Shane E: Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 362:1825-1827, 2010
42. Licata AA: Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 39:668-677, 2005
43. Pischon T, Lahmann PH, Boeing H, et al: Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 98:920-931, 2006 (Pubitemid 44018922)